| Literature DB >> 33505802 |
Piya Prajumwongs1,2, Orawan Waenphimai1,2, Kulthida Vaeteewoottacharn1,2, Sopit Wongkham1,2, Kanlayanee Sawanyawisuth1,2.
Abstract
Reversine is a selective inhibitor of mitotic kinase monopolar spindle 1 (MPS1) and has been reported as an anticancer agent in various cancers. The effects of reversine on bile duct cancer, cholangiocarcinoma (CCA), a lethal cancer in Northeastern Thailand, were investigated. This study reports that reversine inhibited cell proliferation of CCA cell lines in dose- and time-dependent manners but had less inhibitory effect on an immortalized cholangiocyte cell line. Reversine also triggered apoptotic cell death by decreasing anti-apoptotic proteins, Bcl-XL and Mcl-1, increasing Bax pro-apoptotic protein and activating caspase-3 activity. Moreover, reversine induced autophagic cell death by increasing LC3-II and Beclin 1 while decreasing p62. Reversine activated autophagy via the AKT signaling pathway. Additionally, this study demonstrated for the first time that reversine could diminish the expression of Hypoxia-Inducible Factor 1- alpha (HIF-1α) and glucose transporter 1 (GLUT1), resulting in a reduction of glucose uptake and energy production in CCA cell lines. These findings suggest that reversine could be a good candidate as an alternative or supplementary drug for CCA treatment. ©2021 Prajumwongs et al.Entities:
Keywords: Apoptosis; Autophagy; Cholangiocarcinoma; GLUT1; MPS1; Reversine
Year: 2021 PMID: 33505802 PMCID: PMC7797171 DOI: 10.7717/peerj.10637
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984